Зміст
Добірка наукової літератури з теми "Біохімічна лабораторія"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Біохімічна лабораторія".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Біохімічна лабораторія"
Білик, Л. В., О. А. Снісар та К. О. Ліфер. "РОЛЬ І МІСЦЕ БІОЛОГІЧНОЇ ХІМІЇ У СИСТЕМІ ПІДГОТОВКИ ФАХІВЦІВ З МЕДИЧНОЇ РЕАБІЛІТАЦІЇ". Visnik Zaporiz kogo naciohai nogo universitetu Pedagogicni nauki, № 2 (12 листопада 2021): 101–6. http://dx.doi.org/10.26661/2522-4360-2021-2-16.
Повний текст джерелаСмоляр, Н. І., та М. Ю. Лесіцький. "ОСОБЛИВОСТІ ФОСФОРНО- КАЛЬЦІЄВОГО ОБМІНУ В РОТОВІЙ РІДИНІ ДІТЕЙ З РІЗНИМИ РІВНЯМИ РЕЗИСТЕНТНОСТІ ЕМАЛІ ТА ЗУБОЩЕЛЕПНИМИ АНОМАЛІЯМИ". Scientific and practical journal "Stomatological Bulletin" 119, № 2 (26 травня 2022): 88–94. http://dx.doi.org/10.35220/2078-8916-2022-44-2.16.
Повний текст джерелаКлючко, О. М. "МЕДИЧНА ІНФОРМАЦІЙНА СИСТЕМА МОНІТОРИНГУ СТАНУ ЗДОРОВ'Я НАСЕЛЕННЯ ІЗ ЗАХИСТОМ ПЕРСОНАЛЬНИХ ДАНИХ". Medical Informatics and Engineering, № 1 (22 червня 2020): 17–28. http://dx.doi.org/10.11603/mie.1996-1960.2020.1.11126.
Повний текст джерелаХалак, В. І., Б. В. Гутий, М. О. Ільченко та С. Ю. Смислов. "МІНЛИВІСТЬ ТА АСОЦІАТИВНИЙ ЗВ’ЯЗОК ДЕЯКИХ БІОХІМІЧНИХ ПОКАЗНИКІВ СИРОВАТКИ КРОВІ І ФІЗИКО-ХІМІЧНИХ ВЛАСТИВОСТЕЙ М’ЯЗОВОЇ ТКАНИНИ МОЛОДНЯКУ СВИНЕЙ ВЕЛИКОЇ БІЛОЇ ПОРОДИ". Вісник Полтавської державної аграрної академії, № 2 (25 червня 2021): 152–57. http://dx.doi.org/10.31210/visnyk2021.02.18.
Повний текст джерелаVusyk, D. O. "Зміни гематологічних та біохімічних показників крові кішок за піометри до і після лікування". Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies 20, № 83 (26 лютого 2018): 40–43. http://dx.doi.org/10.15421/nvlvet8308.
Повний текст джерелаХалак, Віктор Іванович. "ПОКАЗНИКИ БІЛКОВО ОБМІНУ ТА ЇХ ЗВ'ЯЗОК З ВІДГОДІВЕЛЬНИМИ І М’ЯСНИМИ ЯКОСТЯМИ У МОЛОДНЯКУ СВИНЕЙ РІЗНИХ ГЕНОТИПІВ". Bulletin of Sumy National Agrarian University. The series: Livestock, № 4 (47) (5 січня 2022): 18–23. http://dx.doi.org/10.32845/bsnau.lvst.2021.4.4.
Повний текст джерелаShved, M. I., T. V. Boiko, G. V. Lykhatska, V. I. Boiko та V. O. Lykhatska. "Динаміка клініко-біохімічних показників у хворих на цироз печінки під впливом комплексної терапії із застосуванням урсодезоксихолевої кислоти". GASTROENTEROLOGY, № 4.50 (1 серпня 2013): 57–60. http://dx.doi.org/10.22141/2308-2097.4.50.2013.86382.
Повний текст джерелаStapay, P. V., N. P. Stakhiv, and O. O. Smolyaninova. "Historical essay on the Laboratory of biochemical fundamentals of wool formation." Animal Biology 22, no. 3 (September 2020): 26–31. http://dx.doi.org/10.15407/animbiol22.03.026.
Повний текст джерелаLuchak, M. V., O. Z. Gnateyko, N. R. Kech та G. S. Chaykovska. "Порівняльна оцінка стану гепатобіліарної системи у дітей, які проживають в регіонах, забруднених різними за характером ксенобіотиками". CHILD`S HEALTH, № 3.54 (19 червня 2014): 29–33. http://dx.doi.org/10.22141/2224-0551.3.54.2014.75995.
Повний текст джерелаKhalak, Victor. "МІНЛИВІСТЬ ТА РІВЕНЬ КОРЕЛЯЦІЙНИХ ЗВ’ЯЗКІВ ФІЗИКО-ХІМІЧНИХ ВЛАСТИВОСТЕЙ М’ЯЗОВОЇ ТКАНИНИ ТА ДЕЯКИХ БІОХІМІЧНИХ ПОКАЗНИКІВ СИРОВАТКИ КРОВІ МОЛОДНЯКУ СВИНЕЙ ВЕЛИКОЇ БІЛОЇ ПОРОДИ". Bulletin of Sumy National Agrarian University. The series: Livestock, № 3 (42) (30 листопада 2020): 77–81. http://dx.doi.org/10.32845/bsnau.lvst.2020.3.13.
Повний текст джерелаДисертації з теми "Біохімічна лабораторія"
Стогарь, Т. О., та Олена Михайлівна Проскурня. "Оптимизація діяльності біохімічної лабораторії". Thesis, Національний фармацевтичний університет, 2014. http://repository.kpi.kharkov.ua/handle/KhPI-Press/25035.
Повний текст джерелаЛішневська, Анастасія Геннадіївна, Анастасия Геннадьевна Лишневская та Anastasiia Hennadiivna Lishnevska. "Клінічні, лабораторні та імунологічні зміни при вірусному гепатиті С, залежно від ступеня фіброзу печінки і лікування". Thesis, Сумський державний університет, 2021. https://essuir.sumdu.edu.ua/handle/123456789/86430.
Повний текст джерелаThe dissertation contains a new approach to solving the scientific problem, diagnosis of chronic viral hepatitis C and involves determining the concentration of galectin-9 (Gal-9) in the serum of patients to determine the severity of liver fibrosis, the degree of inflammation, cirrhosis and splenomegaly, predicting the development of autoimmune disorders. The expediency of calculating the indicators of nonspecific immunoreactivity, inflammation and endogenous intoxication before starting antiviral therapy (AVT) and during treatment to determine the autoimmune component of inflammation and the severity of the response of the cellular immune system has been proved. The calculation of non-invasive markers of liver fibrosis is reasoned not only in order to establish the probability of liver fibrosis, but also to assess its degree. The expediency of determination of Gal-9 in the serum of patients with chronic hepatitis C infection in order to establish cirrhosis of the liver and splenomegaly, detection of hepatocellular insufficiency, predicting the development of autoimmune processes in patients receiving interferon-containing therapy is proved. In order to improve the diagnostics of cirrhosis, prediction of immunological disorders in chronic viral hepatitis C based on the study of clinical, hematological, biochemical, integrative features depending on the regimen of antiviral therapy and galectin-9 concentration, patients were included in the study under the following conditions: the presence of chronic hepatitis C infection confirmed by PCR (qualitative). Patients were not included in the study in the presence of comorbidities in the stage of exacerbation and / or decompensation, acute and chronic infectious diseases of other etiologies, cancer and autoimmune diseases, in the case of established alcohol and drug addiction. All patients examined by us signed informed voluntary consent for diagnostics and treatment (form № 003-6o). Examination and treatment of infected persons was carried out in accordance with the Order of the Ministry of Health of Ukraine №729 "On approval and implementation of medical and technological documents for standardization of medical care for viral hepatitis C" from 18.07.2016 and recommendations of the European Association for the Study of the Liver (EASL) 2016 and 2018. The study was conducted in four stages. The first stage was devoted to the study of clinical, hematological, biochemical, immunological features of chronic hepatitis C infection, calculation of integrative indicators and comparison of data in groups with different genotypes of the virus and degrees of activity. The second stage consisted of comparing clinical, laboratory and integrative parameters in patients with different treatment regimens and at different stages of therapy (before the beginning, 4th week, 12th week). In the third stage, correlations between the data obtained and the degree of liver fibrosis F (METAVIR), as well as indicative non-invasive methods for the diagnosis of fibrosis (APRI, FIB-4) were studied. At the fourth stage, the concentration of Gal-9 was determined in patients, and its dependence on laboratory and integrative parameters, treatment regimen, and liver fibrosis was established. In the first three stages, 287 patients with chronic viral hepatitis C and 55 practically healthy individuals who underwent preventive medical examination at the University Clinic of SSU were examined. In the fourth stage, the concentration of galectin-9 was determined in 68 infected and 20 people from the comparison group. All groups were representative by age and sex. All patients underwent physical examination, study of the clinical picture of the disease, clinical blood test (for patients receiving AVT - before it and in the 4th week, 12th week of AVT), biochemical blood test, immunological examination in patients treated with interferon-containing regimen (ELISA to determine the titer of ANA, AMA, ATPO, Anti-Tg Ab), PCR (HCV RNA detection, determining the genotype of the virus), methods for determining the degree of liver fibrosis (fibrotest (METAVIR)). APRI and FIB-4, indicators of non-specific immunoreactivity, inflammation activity and endogenous intoxication were calculated for each patient. In order to study and analyze clinical, hematological, biochemical, immunological features of the course and integrative indicators, patients with chronic viral hepatitis C were divided into groups depending on the degree of activity (minimum activity - 210 people, moderate - 68, severe - 9) and the genotype of the virus (1b - 150 people, 2 - 19, 3a - 102; in 16 people the genotype was not determined or was not determined). It was found that patients of groups with different genotypes were homogeneous on most traits, moreover, in the examined patients: telangiectasias were more common with genotype 1b, as well as serum protein content was higher, alkaline phosphatase (ALP) and creatinine (p <0.05) were lower; hepatomegaly was less common with genotype 2, there was no anemia, creatinine was lower (p <0.05); with genotype 3a, the level of total protein was higher (p <0.05). It is proved that among the examined patients with different degrees of activity, most of the indicators corresponded to the general group. However, in individuals with minimal activity, the level of segmental neutrophils and ESR was higher, lymphocytes and platelets - lower (p <0.05). Among patients with moderate activity, the content of hemoglobin and segmental neutrophils was higher, lymphocytes and platelets were lower (p <0.05). Patients with severe activity had higher ALP, GGTP and total bilirubin, and lower glucose levels (p <0.05). In the general group of patients with chronic viral hepatitis C compared to almost healthy individuals, such higher rates were observed: entropy of leukocyte formula; indices of nonspecific reactivity – resistance coefficient (CR), lymphocyte index (Ilymph), allergy index (IA) (p <0,05); and such lower as neutrophil-monocytes ratio (NMR), eosinophils-lymphocytes ratio (ELR) (p <0,05). All indicators of inflammation were also changed: the total inflammation index (TII) and the Krebs index (KI) decreased; lymphocyte-granulocyte index (ILG), index of leukocyte and ESR ratio (ILESR) (p <0.05) increased. In patients with genotype 2, lower values of TII were observed, with genotype 3a - integrated severity index (ISI), ILESR and intoxication index (II) (p <0.05). In persons with minimal activity, higher values of indicators of endogenous intoxication (aggression index - agrI, hematological index of intoxication - HII, II) were found; lower values were found in patients with moderate activity - nuclear index (NI), leukocyte intoxication index (LII), agrI, II, and in patients with severe activity - agrI (p <0.05). To establish the clinical, hematological, biochemical, autoimmune features of the course and integrative indicators the patients with chronic viral hepatitis C were divided into 4 groups, depending on the AVT regimen at different stages of treatment: basic (pathogenetic and symptomatic; 131 individuals), dual AVT regimen (PEG-IFN + ribavirin, 84); triple (PEG-IFN + ribavirin + sofosbuvir, 25); interferon-free (drugs of direct antiviral action (DDAA), 47). It was found that in patients before treatment, compared with healthy people, there was a decrease in the number of platelets and segmental neutrophils, as well as an increase in lymphocytes (p <0.05). After 4 weeks of treatment, the number of leukocytes and erythrocytes decreased and the ESR increased in the examined patients receiving double and triple therapy. And the number of platelets increased additionally in double therapy (p <0.05). With the use of DDAA in a month only the content of erythrocytes decreased and ESR increased, and at the 12th week a decrease in hemoglobin was found (p <0.05). It was proved that before the start of treatment in the general sample of patients, there was an increase in bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) (p <0,05) in the biochemical analysis of blood. After the fourth week of treatment, ALT, AST, Gamma-glutamyl transpeptidase (GGTP) activity decreased, and the concentration of total bilirubin and alkaline phosphatase (AP) increased (p <0.05) in patients with double and triple therapy. At week 12, these patients had decreased total bilirubin, ALT, AST, GGTP, creatinine, but increased ALT/AST ratio (p <0.05). In patients on interferon-free therapy after 4 weeks, the concentration of total bilirubin, the activity of ALT, AST, GGTP, AP decreased, ALT/AST ratio increased (p <0.05) and remained stable until the end of treatment. Changes in integrative indexes in all examined patients indicated the prevalence of cellular immunity, severe inflammation with a predominance of the autoimmune component. In patients with interferon-containing therapy, the indexes of the dominance of cellular immunity increased, and at 12th week they decreased. Indices of autoimmune inflammation remained elevated throughout treatment. Individuals receiving DDAA had increased rates of inflammation at 4th week and intoxication caused by autoimmune processes. In order to establish clinical, hematological, biochemical features of the course and integrative indicators, patients were divided into 5 groups, depending on the degree of fibrosis (F) (according to Fibrotest (METAVIR): F0 (51 people), F1 (43), F2 (90), F3 (24), F4 (79). Direct correlations were found: between the degree of fibrosis according to METAVIR and FIB-4 (Fibrosis-4 Index for Liver Fibrosis; +0.229, p <0.05); FIB-4 and APRI (AST to Platelet Ratio Index; +0.745, p <0.05) and a tendency to correlate between F (METAVIR) and APRI (+0.635, p = 0.085). There was a direct connection between age, body mass index (BMI) and values of F (METAVIR) (respectively +0.372, p <0.05; +0.183, p <0.05), APRI (+0.215, p <0,05; +0.166, p <0.05), FIB-4 and (+0.657, p <0.05; +0.174, p <0.05). Clinical symptoms (edema-ascites syndrome, telangiectasia, splenic enlargement) had a directly proportional correlation with all non-invasive methods of fibrosis assessment: Fibrotest (METAVIR) (respectively +0.211, +0.183, +0.277; p <0.05), APRI (+0.160) , +0.133, +0.154; p <0.05) and FIB-4 (+0.231, +0.154, +0.337; p <0.05), direct link was established between F (METAVIR), FIB-4 and asthenovegetative syndrome (respectively +0,155, +0,126; p <0,05), between F (METAVIR), APRI and increase in liver size (+0,139, +0,130; p <0,05). An inversely proportional correlation was found between the values of F (METAVIR), APRI, FIB-4 and the level of platelets (respectively -0.164, -0.644, -0.700; p <0.05); between APRI, FIB-4 and the number of leukocytes (-0.225, -0.291, p <0.05); FIB-4 and the number of erythrocytes (-0.228, p <0,05). A direct relationship was observed between APRI, FIB-4 and ESR (+ 0.159, + 0.308, p <0.05). Data from all three methods were directly proportionally correlated with the content of total bilirubin (F (METAVIR) + 0.219; APRI + 0.261; FIB-4 + 0.248; p <0.05); F (METAVIR) had feedback, and APRI, FIB-4 - direct with ALT (-0.230, + 0.737, + 0.247; p <0.05), AST (-0.125, + 0.891, + 0.531; p < 0.05) and GGTP (-0.113, + 0.396, + 0.149; p <0.05). Also, the results of F (METAVIR) had a direct correlation with AP (+ 0.283, p <0.05), F (METAVIR), FIB-4 - with ALT/AST ratio (+ 0.302, + 0.345; p <0.05). A directly proportional relationship was found between F (METAVIR) and ISI (+ 0.189, p <0.05), ILESR (+ 0.188, p <0.05) and between FIB-4 and ISI (+ 0.187, p < 0.05). Inversely proportional correlation between F (METAVIR) and immunoreactivity index (IR) (-0.204, p <0.05), NLR (-0.131, p <0.05), LMR (-0.206, p <0, 05); between APRI and entropy of leukocyte formula (-0.145, p <0.05), agrI; between FIB-4 and IR (-0.110, p <0.05). The concentration of Gal-9 was determined in 88 people: all patients were divided into 3 groups, depending on the treatment: basic therapy (pathogenetic and symptomatic) - 20 people, Peg-IFN in combination with ribavirin - 24 people, velpatasvir with sofosbuvir - 24 people. Also, the amount of Gal-9 was determined in 20 healthy individuals (comparison group). Infected with hepatitis C virus had higher levels of Gal-9 compared with healthy ones (p <0.05). The use of PEG-IFN and ribavirin in the treatment significantly increased the lectin content in patients with chronic viral hepatitis C (p <0.05). There was a tendency to decrease of Gal-9 under the influence of sofosbuvir and velpatasvir, compared with patients without AVT (p = 0.073). It was found that the increase in the concentration of Gal-9 correlated with an increase in F (METAVIR; +0.550; p <0.05), APRI (+0.505; p <0.05), FIB-4 (+0.448; p <0.05 ), ALT/AST ratio (+0.448, p <0.05) and a decrease in platelet count (-0.531, p <0.05), which proves the feasibility of determining the amount of lectin in the serum of patients with chronic viral hepatitis C for liver fibrosis and hepatocellular insufficiency. Inversely proportional correlation between the content of Gal-9 at the 4th week of interferon-containing AVT and NI at the 12th week (-0.424, p <0.05) allows to predict the severity of the inflammatory response in patients with chronic viral hepatitis C during treatment. It is proved that at the concentration of Gal-9 above 8360 pg / l at the 4th week of interferon-containing AVT there is a high probability of autoimmune processes, which is confirmed by the detection of positive antinuclear antibodies (ANA) at 12th week (sensitivity (Se) - 75.0%, specificity (Sp) - 68.7%). In patients who did not receive AVT, with a Gal-9 above 3929 pg / ml, it is possible to predict the presence of liver cirrhosis (Se - 75.0%, Sp - 81.2%), and above 4829 pg / ml - splenomegaly - 100.0%, Sp - 88.9%).